Patients report on HS symptom relief after new drug start
NCT ID NCT06444087
First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study follows 192 adults with hidradenitis suppurativa (HS) for 12 months after they start taking secukinumab. Researchers ask patients to rate their pain, oozing, and bad smell on a 0-10 scale. The goal is to see how many patients get at least a 30% reduction in these symptoms. This is an observational study, meaning no extra treatments are given—just tracking real-world results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nice, France, 06000, France
-
Novartis Investigative Site
Antony, 92160, France
-
Novartis Investigative Site
Bordeaux, 33075, France
-
Novartis Investigative Site
Brest, 29609, France
-
Novartis Investigative Site
Calais, 62100, France
-
Novartis Investigative Site
Dijon, 21000, France
-
Novartis Investigative Site
La Rochelle, 17019, France
-
Novartis Investigative Site
Le Mans, 72000, France
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Lorient, 56322, France
-
Novartis Investigative Site
Lyon, 69003, France
-
Novartis Investigative Site
Marseille, 13008, France
-
Novartis Investigative Site
Martigues, 13500, France
-
Novartis Investigative Site
Montpellier, 34090, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Paris, 75014, France
-
Novartis Investigative Site
Rodez, 12000, France
-
Novartis Investigative Site
Rouen, 76031, France
-
Novartis Investigative Site
Saint-Mandé, 94160, France
-
Novartis Investigative Site
Saint-Pierre, 97410, France
-
Novartis Investigative Site
Toulouse, 31400, France
-
Novartis Investigative Site
Vannes, 56000, France
Conditions
Explore the condition pages connected to this study.